Loading
A phase 1/2 trial of Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine in colorectal cancer, run by Boehringer Ingelheim, now recruiting.
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread is a phase 1/2 interventional study registered as NCT06324357 by Boehringer Ingelheim, with 768 participants planned, started 2024-06-28 and due to reach its primary completion in 2029-01-08. Interventions recorded: Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine. Conditions listed: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors.
Shares HER2-amplified colorectal cancer, Trastuzumab, Colorectal cancer.
Shares Zongertinib, Boehringer Ingelheim, Trastuzumab deruxtecan, Small-molecule kinase inhibitors.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors.
Shares HER2-amplified colorectal cancer, Trastuzumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Small-molecule kinase inhibitors.
Shares HER2-amplified colorectal cancer, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/